Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma.

Read more here:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472875.htm